A2B AntagonistA2A Antagonist
Targeted Adenosine
Receptor Blockade
Cyncado Therapeutics is a clinical stage biotech company advancing investigational A2B receptor antagonism and co-administered A2B/A2A adenosine receptor blockade for mesothelioma and other cancers with high unmet medical need.
One Pathway. Multiple Diseases. Selective By Design.
50+
Granted Patents Across Global Jurisdictions
3
Clinical Assets
3
Therapeutic Areas
15+
World-Leading Experts
Cyncado is advancing a differentiated adenosine oncology platform supported by 50+ granted patents across global jurisdictions, multiple clinical-stage assets, priority cancer indications, and experienced scientific and global clinical leaders focused on mesothelioma and other cancers with high unmet medical need.